Slingshot members are tracking this event:
Actinium Pharma (ATNM) Receives Guidance from European Medicines Agency Regarding Phase 3 SIERRA Study Evaluating Iomab-B in Acute Myeloid Leukemia
Slingshot Insights Explained
Mar 21, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Guidance, European Medicine's Agency, Ema, Phase 3, Sierra, Iomab-b, Acute Myeloid Leukemia